VATS vs. open lobectomy for early stage non-small cell lung cancer

Shawn S. Groth; Michael A Maddaus

doi:10.1007/978-1-84996-492-0_8

VATS vs. open lobectomy for early stage non-small cell lung cancer

Shawn S. Groth, Michael A Maddaus

Surgery

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Of the estimated 219,440 people in the United States who will be diagnosed with lung cancer in 2009,¹ about 13% (32,900 people) will have early stage (American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).^2,3 Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%. ⁴ - ⁶ Radiation and chemotherapy (alone or in combination) offer little survival benefit. Only patients who undergo complete surgical resection are afforded a significant chance at long-term survival.^7-9 Because early stage tumors are confined within a focus of lung parenchyma, the goal of pulmonary resection for early stage NSCLC is to obtain local control of the tumor, thereby preventing future tumor dissemination. The current standard of care for treating early stage NSCLC patients with sufficient cardiopulmonary reserve is a lobectomy^10,11 and complete mediastinal lymph node dissection.^12,13

Original language	English (US)
Title of host publication	Difficult Decisions in Thoracic Surgery (Second Edition)
Subtitle of host publication	An Evidence-Based Approach
Publisher	Springer London
Pages	77-88
Number of pages	12
ISBN (Print)	9781849963640
DOIs	https://doi.org/10.1007/978-1-84996-492-0_8
State	Published - Dec 1 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/978-1-84996-492-0_8

Find It

Find It at U of M Libraries

Cite this

@inbook{df4963622cb34fc393502fcfe240fdd2,

title = "VATS vs. open lobectomy for early stage non-small cell lung cancer",

abstract = "Of the estimated 219,440 people in the United States who will be diagnosed with lung cancer in 2009,1 about 13% (32,900 people) will have early stage (American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).2,3 Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%. 4 - 6 Radiation and chemotherapy (alone or in combination) offer little survival benefit. Only patients who undergo complete surgical resection are afforded a significant chance at long-term survival.7-9 Because early stage tumors are confined within a focus of lung parenchyma, the goal of pulmonary resection for early stage NSCLC is to obtain local control of the tumor, thereby preventing future tumor dissemination. The current standard of care for treating early stage NSCLC patients with sufficient cardiopulmonary reserve is a lobectomy10,11 and complete mediastinal lymph node dissection.12,13",

author = "Groth, {Shawn S.} and Maddaus, {Michael A}",

year = "2011",

month = dec,

day = "1",

doi = "10.1007/978-1-84996-492-0_8",

language = "English (US)",

isbn = "9781849963640",

pages = "77--88",

booktitle = "Difficult Decisions in Thoracic Surgery (Second Edition)",

publisher = "Springer London",

address = "United Kingdom",

}

TY - CHAP

T1 - VATS vs. open lobectomy for early stage non-small cell lung cancer

AU - Groth, Shawn S.

AU - Maddaus, Michael A

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Of the estimated 219,440 people in the United States who will be diagnosed with lung cancer in 2009,1 about 13% (32,900 people) will have early stage (American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).2,3 Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%. 4 - 6 Radiation and chemotherapy (alone or in combination) offer little survival benefit. Only patients who undergo complete surgical resection are afforded a significant chance at long-term survival.7-9 Because early stage tumors are confined within a focus of lung parenchyma, the goal of pulmonary resection for early stage NSCLC is to obtain local control of the tumor, thereby preventing future tumor dissemination. The current standard of care for treating early stage NSCLC patients with sufficient cardiopulmonary reserve is a lobectomy10,11 and complete mediastinal lymph node dissection.12,13

AB - Of the estimated 219,440 people in the United States who will be diagnosed with lung cancer in 2009,1 about 13% (32,900 people) will have early stage (American Joint Committee on Cancer [AJCC] stage I and II) non-small cell lung cancer (NSCLC).2,3 Patients with untreated stage I NSCLC, albeit an early stage neoplasm, have a 5-year survival rate of less than 5%. 4 - 6 Radiation and chemotherapy (alone or in combination) offer little survival benefit. Only patients who undergo complete surgical resection are afforded a significant chance at long-term survival.7-9 Because early stage tumors are confined within a focus of lung parenchyma, the goal of pulmonary resection for early stage NSCLC is to obtain local control of the tumor, thereby preventing future tumor dissemination. The current standard of care for treating early stage NSCLC patients with sufficient cardiopulmonary reserve is a lobectomy10,11 and complete mediastinal lymph node dissection.12,13

UR - http://www.scopus.com/inward/record.url?scp=84889957965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889957965&partnerID=8YFLogxK

U2 - 10.1007/978-1-84996-492-0_8

DO - 10.1007/978-1-84996-492-0_8

M3 - Chapter

AN - SCOPUS:84889957965

SN - 9781849963640

SP - 77

EP - 88

BT - Difficult Decisions in Thoracic Surgery (Second Edition)

PB - Springer London

ER -

VATS vs. open lobectomy for early stage non-small cell lung cancer

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this